Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The widespread application of GLP-1 receptor agonists at the population level may impose significant financial pressure on pharmaceutical budgets, with modeling studies indicating that treating all eligible individuals with diabetes and obesity might need a 1020% rise in drug expenditures in several nations
It was developed by Eli Lilly, the same company behind tirzepatide
Were in new territory where obesity and type 2 diabetes medications treat an underlying cause instead of merely treating the symptoms to support better management
And it is the most misunderstood
Faulkner, R
US$ 27.85
US$ 21.28
US$ 27.96
